4-Fluoronitrobenzene | CAS:350-46-9

We serve 4-Fluoronitrobenzene CAS:350-46-9 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
4-Fluoronitrobenzene

Chemical Name:4-Fluoronitrobenzene
CAS.NO:350-46-9
Synonyms:4-Fluoronitrobenzene
P-FLUORONITROBENZENE
Benzene, 1-fluoro-4-nitro-
4-Fluornitrobenzol
1-Fluor-4-nitrobenzol
Molecular Formula:C6H4FNO2
Molecular Weight:141.10000
 
Physical and Chemical Properties:
Density:1.33
Melting point:21ºC
Boiling point:205ºC
Flash point:182°F
Index of Refraction:1.531
 
Specification:
Appearance:Light yellow transparent liquid
Assay:≥99.5%
Moisture:≤0.2%
 
Packing:200 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:Organic synthesis intermediate



Contact us for information like 4-Fluoronitrobenzene chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,1-Fluor-4-nitrobenzol physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,P-FLUORONITROBENZENE Use and application,P-FLUORONITROBENZENE technical grade,usp/ep/jp grade.


Related News: Bulk bulk medicines: overcapacity, low prices, future capacity and output will be reduced, and it is possible to transfer foreign production.4-tert-Butylbenzylamine manufacturer ViiV, in which Pfizer and Shionogi have small stakes, said it received a so-called complete response letter (CRL) from the FDA in which the regulator questioned the treatment’s chemistry, manufacturing and controls process, but not its safety.4-(trifluoromethyl)phenol supplier It’s the first confirmed Wuhan coronavirus death from outside of mainland China, and brings the total toll to 305.N,N-dimethyl-1,4-phenylenediamine vendor With the global industrial division of labor and the change in the business model of multinational pharmaceutical companies, the outsourced market for patented drug substances will further expand.“Inceptua Medicines Access is delighted to be selected as Onconova’s partner for the Pre-approval Access Program for rigosertib.